PDF icon Download PDF
Digestive Disease Interventions
DOI: 10.1055/s-0045-1808265
Review Article

New Insights in Diagnosing and Risk-Stratifying Pancreatic Cystic Neoplasms and IPMN

Tommaso Pollini 
1   Division of Surgical Oncology, Department of Surgery, University of California San Francisco, San Francisco, California
,
Ajay V. Maker
1   Division of Surgical Oncology, Department of Surgery, University of California San Francisco, San Francisco, California
› Author Affiliations
Funding Acknowledgement to the Shorenstein Family Foundation, Baker and Simpson Family Research Fund, Illinois Ventures, and Inner Child Foundation.
› Further Information
Also available ateRef
   Permissions and Reprints
Preview

Abstract

Pancreatic cystic neoplasms (PCN) comprise a diverse group of lesions with variable malignant potential, requiring accurate diagnosis and risk stratification for appropriate management. Distinguishing mucinous cysts, including intraductal papillary mucinous neoplasms (IPMN) and mucinous cystic neoplasms (MCN), from benign nonmucinous lesions such as serous cystadenomas (SCA) is essential due to their risk of progression to invasive carcinoma. Importantly, IPMN and MCN represent the only radiologically detectable precursors to pancreatic cancer, contributing to 15% of cases. Traditional diagnostic approaches utilize imaging modalities like computed tomography, magnetic resonance imaging, and endoscopic ultrasound (EUS), often supported by cyst fluid analysis through fine-needle aspiration. However, these techniques exhibit limited sensitivity and specificity in identifying malignant transformation. Emerging molecular diagnostics, including analysis of carcinoembryonic antigen, glucose, IL1β, PGE2, and DNA sequencing for mutations such as KRAS and GNAS, show promise in differentiating mucinous cysts and identifying advanced dysplasia. Despite this, clinical integration remains limited. Future efforts focus on noninvasive methods, including plasma-based liquid biopsies, to complement cyst fluid analysis. A comprehensive biomarker panel integrating serum and cyst fluid markers holds the potential to improve early detection, reduce overtreatment, and optimize surgical management of high-risk PCN.

Keywords

IPMN - pancreas - pancreatic cystic neoplasms - intraductal papillary mucinous neoplasms


Publication History

Received: 24 January 2025

Accepted: 08 April 2025

Article published online:
19 May 2025

© 2025. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA